Meanwhile, EDIL3 immunoreactivity was exclusively distributed in tumor cells, but not any positive staining in other cells except islet cells, such as immune cell and stromal cell, suggesting that EDIL3 might constitute an autocrine network in regulating tumor progression in PDAC and indicating that elevated EDIL3 expression might associate with prognosis of PDAC patients. This evidence concerns the gene EDIL3 and neoplasm.